Happy #LabWeek! This week, we celebrate the hard work, dedication and commitment of our laboratory team members who play a vital role in healthcare and improving patient outcomes. Together, we continued to launch new tests in important therapeutic areas including oncology, women’s health, autoimmune and neurology. Thank you for all that you do.
We recognize the link between human and environmental health and the leading role our company plays in creating a healthier world. We are proud to share our progress on initiatives that positively impact our employees, operations and the communities we serve. View our latest Corporate Responsibility Report!
Labcorp launches Labcorp® Plasma Detect™, extending leadership into molecular residual disease (MRD) clinical research. The launch of the Labcorp Plasma Detect MRD solution further enhances Labcorp's leadership in precision oncology across the solid tumor oncology care continuum.
Labcorp launches Labcorp® Plasma Detect™, extending leadership into molecular residual disease (MRD) clinical research. Labcorp Plasma Detect is the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution in early-stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). #AACR24 #Oncology #PrecisionMedicine #MRD #ctDNA
We are excited to share that Inception Fertility has selected Labcorp to provide genetic carrier screening and related services, like genetic counseling, for patients of The Prelude Network®. This expanded partnership also supports the Genetic Center of Excellence program commitment to establish standardized, best-in-class genetic screening for patients and egg donors in Prelude's network.
PTau-217 is here. Labcorp is proud to make this test widely available to clinicians and biopharma partners for their patients. The launch of our pTau-217 test extends Labcorp’s leadership in Alzheimer’s testing, complementing our current portfolio of blood-based biomarkers including beta amyloid 42/40 ratio (available in Europe as a CE-marked assay) and neurofilament light chain (NfL) assay. #Alzheimers #ptau217 #Biomarkers
Did you know that women make around 80% of the healthcare decisions for their families yet are often left without the time to look after their own health needs? As #WomensHistoryMonth comes to a close, Labcorp is committed to helping amplify the voices of women, encouraging them to advocate for their health and well-being. Hear our inspiring patient stories and learn how to prioritize your well-being, all year round.
Today, Labcorp announced it has entered into an agreement to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO. Through this transaction, Labcorp will acquire BioReference Health’s laboratory testing businesses focused on clinical diagnostics and reproductive and women’s health across the United States outside of New York and New Jersey. This transaction includes patient service centers (PSCs) and certain customer contracts and operating assets. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New York and New Jersey. We look forward to providing patients with expanded access to comprehensive, high-quality clinical laboratory services while enhancing our laboratory services network nationwide.
For the third consecutive year, colleagues across Labcorp rallied together to lift the spirits of hospitalized children through the “Cards of Encouragement Campaign.” More than 2,000 of our employees created and submitted just over 6,500 cards that, with the help of nonprofit Cards for Hospitalized Kids, will be distributed to 62 children’s hospitals and Ronald McDonald Houses around the globe.
Labcorp is excited to partner with Tigerlily Foundation and Maimah Karmo, Tigerlily founder and CEO, to eradicate barriers for medically underserved communities to be included in clinical trials. As we jointly launch our I Am Included Framework, our hope is that this actionable framework will enable site leaders to leverage the insights and best practices to make clinical trials more inclusive everywhere.
